Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Increased Prevalence of Antibodies to Hepatitis E Virus in Patients with Neurocysticercosis.

The American journal of tropical medicine and hygiene·2024
Same author

International multicenter study comparing demographics, therapy and outcomes in bleeding from Mallory Weiss tears and peptic ulcers.

Endoscopy international open·2022
Same author

Serological evidence of hepatitis E virus infection in pigs from Northern Bulgaria.

Veterinaria italiana·2021
Same author

Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation.

Kidney international·2021
Same author

Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2.

Viruses·2021
Same author

High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2021
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: May 22, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Hepatitis E. La hepatitis E es una enfermedad muy común.

Nassim Kamar1, Richard Bendall2, Florence Legrand-Abravanel3

  • 1Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France; Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France; Université Paul Sabatier, Toulouse, France.

Lancet (London, England)
|May 3, 2012
PubMed
Resumen
Este resumen es generado por máquina.

El virus de la hepatitis E (VHE), una causa común de hepatitis viral aguda a nivel mundial, fue descubierto en la década de 1980. Los hallazgos recientes revelan que el HEV está presente en los países desarrollados, cambiando nuestra comprensión de su impacto mundial en la salud.

Más Videos Relacionados

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Videos de Experimentos Relacionados

Last Updated: May 22, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Área de la Ciencia:

  • * Virología y Epidemiología.
  • * Enfermedades infecciosas.
  • * Salud Pública * Salud Pública

Sus antecedentes:

  • * El virus de la hepatitis E (VHE) surgió durante la ocupación soviética de Afganistán en la década de 1980, identificado inicialmente a través de un brote de hepatitis en un campamento militar.
  • * El virus fue detectado por microscopía electrónica en un investigador que ingirió materia fecal de soldados infectados.
  • * El HEV es ahora reconocido como la principal causa de hepatitis viral aguda a nivel mundial, particularmente endémico en regiones pobres en recursos.

Objetivo del estudio:

  • * Para presentar recientes descubrimientos científicos relacionados con el virus de la hepatitis E (VHE).
  • * Para aclarar cómo los nuevos hallazgos han remodelado la comprensión global del impacto de HEV en la salud humana.
  • * Para resaltar la evolución de la epidemiología de HEV, incluyendo su presencia en las naciones desarrolladas.

Principales métodos:

  • * Revisión de la literatura científica y los hallazgos recientes de la investigación sobre HEV.
  • * Análisis de datos epidemiológicos y informes clínicos relacionados con las infecciones por HEV.
  • * Síntesis de información sobre la detección, la transmisión y la carga de la enfermedad de HEV.

Principales resultados:

  • * Inicialmente se creía que el HEV estaba confinado a áreas endémicas específicas.
  • * Estudios recientes confirman la presencia y la importancia de HEV en los países desarrollados.
  • * El impacto en la salud mundial del VHE es más generalizado de lo que se suponía anteriormente.

Conclusiones:

  • * La hepatitis E es un importante problema de salud mundial, que prevalece en todo el mundo.
  • * La distribución geográfica y el impacto de los HEV son más amplios de lo inicialmente reconocido.
  • * La investigación en curso es crucial para gestionar y mitigar los efectos de HEV a nivel mundial.